文献速递临床免疫分子诊断质量管理与危急值

自动化化学发光SARS-CoV-2 IgG检测的性能评估

Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay.
PubMed 文献 · Clin Chim Acta · 2020-09-08

该研究评估Abbott SARS-CoV-2 IgG在Architect免疫分析仪上的性能,包括精密度、灵敏度、特异性、预测值、交叉反应和样本通量。特异性99.8%(n=980),灵敏度45.9-96.7%(n=279);RT-PCR阳性≥14天时PPV/NPV为96.4%/99.8%。将阳性判定阈值降至≥0.55可提高灵敏度但特异性略降至98.9%。

要点

  • 该检测在RT-PCR阳性≥14天患者中表现优异,PPV/NPV达96.4%/99.8%。
  • 交叉反应极少,与流感、登革热、乙肝/丙肝、RF、ANA、dsDNA、梅毒抗体无明显交叉。
  • 降低阳性判定阈值至≥0.55可提高早期(0-6天)灵敏度至45.9-55.8%,特异性略降至98.9%。

核心结论

  • Abbott SARS-CoV-2 IgG检测在RT-PCR阳性≥14天的患者中性能优异。
  • 医护人员与疫情前样本的COI差异数值很小(0.01,p<0.0001)。
  • 降低COI阳性判定阈值可提高灵敏度但轻微降低特异性。

研究设计与样本

  • 评估Abbott SARS-CoV-2 IgG在Architect免疫分析仪上的性能。
  • 样本来自RT-PCR阳性患者、医护人员及疫情前样本。
  • 评估指标包括精密度、灵敏度、特异性、PPV/NPV、交叉反应和样本通量。
  • 比较所有对照样本(医护人员和疫情前)的COI以生成优化的阳性判定阈值。

主要发现

  • 特异性99.8%(n=980),灵敏度45.9-96.7%(n=279)。
  • RT-PCR阳性≥14天时PPV/NPV为96.4%/99.8%。
  • 医护人员与疫情前样本的COI差异为0.01(p<0.0001)。
  • 与其他抗体(流感/登革热/乙肝/丙肝/RF/ANA/dsDNA/梅毒)交叉反应极小。
  • 样本通量为70分钟100个样本。

关键数值与推荐

  • 特异性99.8%(n=980),灵敏度45.9-96.7%(n=279)。
  • RT-PCR阳性≥14天时PPV/NPV为96.4%/99.8%。
  • 基于对照99百分位COI和ROC分析,优化阳性判定阈值为≥0.55。
  • 阈值≥0.55时,0-6天阳性样本灵敏度为45.9-55.8%,特异性为98.9%。
  • 医护人员与疫情前样本COI差异0.01(p<0.0001)。

临床怎么用

  • 该检测适用于RT-PCR阳性≥14天患者的抗体评估。
  • 降低阳性判定阈值至≥0.55可提高早期诊断灵敏度,但需注意特异性轻微下降。
  • 交叉反应极少,可减少假阳性干扰。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: We describe our evaluation of the Abbott SARS-CoV-2 IgG assay on the Architect immunoassay analyser. METHODS: We assessed assay precision, sensitivity, specificity, positive/negative predictive values (PPV/NPV), cross-reactivity (influenza/dengue/hepatitis B and C/rheumatoid factor/anti-nuclear/double-stranded DNA/syphilis) and sample throughput in samples from real-time polymerase chain reaction (RT-PCR) positive patients/healthcare workers (HCWs)/pre-pandemic samples. We compared the cut-off indexes (COIs) between all control samples (HCWs and pre-pandemic) to generate an optimised COI limit for reactivity. RESULTS: The assay specificity was 99.8% (n = 980) and sensitivity was 45.9-96.7% (n = 279). When tested ≥ 14 days post-positive RT-PCR (POS), the PPV/NPV was 96.4%/99.8%. The difference between the COIs of HCWs/pre-pandemic samples was small (0.01, p < 0.0001). There was minimal cross-reactivity with other antibodies. A lower COI limit for reactivity (≥0.55, using the 99th percentile COI of our controls and ROC analysis) improved diagnostic sensitivity, especially at 0-6 days POS (45.9-55.8%), with a small decrease in specificity (98.9%). The assay throughput was 100 samples in 70 min. CONCLUSION: The Abbott SARS-CoV-2 IgG assay shows excellent performance in patients ≥ 14 days POS. The difference between the COIs of HCWs and pre-pandemic samples was numerically small. A lower COI limit improves assay sensitivity with a slight decrease in specificity.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Lau CS, Oh HML, Hoo SP, et al. Performance of an automated chemiluminescence SARS-CoV-2 IG-G assay. Clin Chim Acta. 2020. PMID: 32910979. doi:10.1016/j.cca.2020.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。